Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Reports linked discontinuing Mounjaro and Zepbound to hallucinations, mania, and other psychiatric symptoms. Separate coverage noted GLP-1s were tied to fewer psychiatric hospitalisations in schizophrenia and were being studied for alcohol and opioid addiction. The story quieted without a definitive conclusion in the coverage.
Epilogue added 2d ago, after coverage quieted.
The brief
New case reports in The Primary Care Companion CNS Disorders describe two men who experienced psychiatric symptoms after stopping tirzepatide, according to the New York Post. The Post said research is only beginning to uncover the psychiatric effects of stopping a drug that may affect how the brain processes mood and rewards.
The first case involved a 61-year-old man who stopped tirzepatide, sold under the brand names Mounjaro and Zepbound, in August 2025 because of nausea. Two months later, he was hospitalized for worsening confusion and erratic behavior. According to the Post, doctors noted paranoia, auditory and visual hallucinations and Cotard's delusion, a condition in which a patient believes they are dead or do not exist. His symptoms met the criteria for a psychotic disorder.
Although the man had a history of depression, the Post reported that his condition worsened significantly in the month before his hospitalization. Tests on his cerebrospinal fluid, along with brain MRIs and an electroencephalogram, all came back normal, ruling out several other causes. Doctors told him to continue his antidepressant, Zoloft, and put him on two other antipsychotics, Zyprexa and Haldol.
His psychotic symptoms and depression initially improved enough for him to return home, but he was readmitted weeks later for depression with catatonic features, becoming motionless and unresponsive. The Post said he ultimately required inpatient care and was treated with electroconvulsive therapy.
The second case involved a 52-year-old patient who stopped the same medication abruptly in September 2025 after significant weight loss. The Post reported that he had shed 100 pounds over six months. The source text provided ends at that point, so it does not describe his psychiatric symptoms, diagnosis or treatment.
The Post also reported that by the end of their first year on GLP-1s, more than half of patients stop taking the medication. It listed high costs, unpleasant side effects and satisfaction with the weight already lost as reasons, and said the catch is that the weight is likely to come back fast after stopping the medication.
The other coverage in this trend focused on possible new uses for GLP-1 drugs rather than withdrawal effects. The Pharmacist reported that semaglutide will be tested as a treatment for alcohol and opioid addiction, while the Baylor College of Medicine Blog Network described a VA trial to study the effects of GLP-1s for alcohol use disorder among veterans. Yahoo Health covered the idea that GLP-1s may help with more than food cravings, and Psychiatric Times examined what the Post called "The Ozempic Dilemma: Promises and Pitfalls in Psychiatry."
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 5d ago.
Quick answers
What psychiatric symptoms were reported after stopping tirzepatide?
According to the New York Post, a 61-year-old man who stopped tirzepatide in August 2025 was hospitalized two months later with paranoia, auditory and visual hallucinations, and Cotard's delusion, a condition in which a patient believes they are dead or do not exist. His symptoms met the criteria for a psychotic disorder.
What happened to the 61-year-old man after he was hospitalized?
The New York Post reported that doctors told him to continue his antidepressant, Zoloft, and put him on two other antipsychotics, Zyprexa and Haldol. His psychotic symptoms and depression initially improved enough for him to return home, but he was readmitted weeks later for depression with catatonic features and ultimately required inpatient care and electroconvulsive therapy.
Why do some people stop taking GLP-1 drugs?
The New York Post said high costs, unpleasant side effects and satisfaction with the weight already lost are among the reasons patients stop. It also reported that by the end of their first year on GLP-1s, more than half of patients stop taking the medication, and that the weight is likely to come back fast.
Coverage (8)
- Discontinuing Mounjaro and Zepbound Linked to Psychiatric Symptoms India News Network · 5d ago
- Stopping Mounjaro & Zepbound May Trigger Hallucinations, Mania & Other Psychiatric Symptoms Health and Me · 5d ago
- GLP-1s Tied to Fewer Psychiatric Hospitalisations in Schizophrenia EMJ · 5d ago
- The Ozempic Dilemma: Promises and Pitfalls in Psychiatry Psychiatric Times · 5d ago
- Semaglutide to be tested as treatment for alcohol and opioid addiction The Pharmacist · 5d ago
- GLP-1s May Help With More Than Food Cravings Yahoo Health · 5d ago
- VA trial to study effects of GLP-1s for alcohol use disorder among veterans Baylor College of Medicine Blog Network - · 5d ago
- Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs New York Post · 5d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk announces trial data showing Wegovy injection reduces BMI and obesity rates in children as young as six, expanding weight-loss drug use to elementary-age patients.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
DJ Khaled reflects on using GLP-1s in 90-pound weight loss journey: ‘I needed help’
DJ Khaled publicly details a 75-to-90-pound weight loss aided by GLP-1 medication Wegovy, sparking wide entertainment-media coverage.